These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33823761)

  • 1. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
    Agrahari V; Agrahari V
    Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
    Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
    Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current hurdles to the translation of nanomedicines from bench to the clinic.
    Đorđević S; Gonzalez MM; Conejos-Sánchez I; Carreira B; Pozzi S; Acúrcio RC; Satchi-Fainaro R; Florindo HF; Vicent MJ
    Drug Deliv Transl Res; 2022 Mar; 12(3):500-525. PubMed ID: 34302274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation.
    Zagalo DM; Sousa J; Simões S
    Eur J Pharm Biopharm; 2022 Sep; 178():1-24. PubMed ID: 35908664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
    Rawal M; Singh A; Amiji MM
    Pharm Res; 2019 Sep; 36(11):153. PubMed ID: 31482243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
    Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
    Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.
    Ramos TI; Villacis-Aguirre CA; López-Aguilar KV; Santiago Padilla L; Altamirano C; Toledo JR; Santiago Vispo N
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes.
    Dri DA; Rinaldi F; Carafa M; Marianecci C
    Drug Deliv Transl Res; 2023 Mar; 13(3):757-769. PubMed ID: 36450964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro dissolution considerations associated with nano drug delivery systems.
    Gupta R; Chen Y; Xie H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1732. PubMed ID: 34132050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Nanomedicine: A Revolution at the Nanoscale.
    Fornaguera C; García-Celma MJ
    J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.